

Resource Summary Report

Generated by [dkNET](#) on Aug 2, 2026

Ultra-LEAF(TM) Purified anti-human CD3

RRID:AB_11147370

Type: Antibody

Proper Citation

BioLegend Cat# 317325, RRID:AB_11147370

Antibody Information

URL: http://antibodyregistry.org/AB_11147370

Proper Citation: BioLegend Cat# 317325, RRID:AB_11147370

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Ultra-LEAF(TM) Purified anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone OKT3

Antibody ID: AB_11147370

Vendor: BioLegend

Catalog Number: 317325

Alternative Catalog Numbers: 317350, 317349, 317326, 317348, 317347

Record Creation Time: 20250820T002212+0000

Record Last Update: 20250820T080516+0000

Ratings and Alerts

No rating or validation information has been found for Ultra-LEAF(TM) Purified anti-human CD3.

No alerts have been found for Ultra-LEAF(TM) Purified anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Zhang M, et al. (2025) Microbiota-derived urocanic acid triggered by tyrosine kinase inhibitors potentiates cancer immunotherapy efficacy. *Cell host & microbe*, 33(6), 915.

Huang L, et al. (2025) Interferon-driven CAF reprogramming augments immunogenic response to neoadjuvant radiotherapy in colorectal cancer. *Cell reports. Medicine*, 6(8), 102251.

Moore GL, et al. (2025) A B7-H3-Targeted CD28 Bispecific Antibody Enhances the Activity of Anti-PD-1 and CD3 T-cell Engager Immunotherapies. *Molecular cancer therapeutics*, 24(3), 331.

Stockmann AP, et al. (2025) DF6215, an α -optimized IL-2-Fc fusion, expands immune effectors and drives robust preclinical anti-tumor activity. *Cell reports. Medicine*, 102518.

Ma H, et al. (2024) Pirin Inhibits FAS-Mediated Apoptosis to Support Colorectal Cancer Survival. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 11(10), e2301476.

Kim Y, et al. (2024) Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor. *Cell host & microbe*, 32(8), 1380.

Xu F, et al. (2023) Prostate cancer cell-derived exosomal IL-8 fosters immune evasion by disturbing glucolipid metabolism of CD8⁺ T cell. *Cell reports*, 42(11), 113424.

Wu M, et al. (2023) Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow-Derived Macrophages. *Cancer research*, 83(5), 771.

Babin L, et al. (2022) De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK⁺ ALCL pathogenesis and reveals the ROR2 receptor as target for tumor cells. *Molecular cancer*, 21(1), 65.

Mancuso RV, et al. (2020) Anti- α L β 2 antibodies reveal novel endocytotic cross-modulatory functionality. *British journal of pharmacology*, 177(12), 2696.